跳至主要内容
临床试验/NCT02425449
NCT02425449已完成4 期

Characterizing Fade Upon Train-of Four Stimulation During Onset and Offset of Neuromuscular Block Produced by Succinlycholine

University of Toledo Health Science Campus1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2015年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
19
试验地点
1
主要终点
Fade on Train of Four Stimulation

研究概览

简要总结

Muscle relaxants are medications used during surgery to facilitate surgical access. The effect of the muscle relaxant medications is measured by stimulation a motor nerve and measuring the force of the resultant muscle contraction. Based on the mechanism of action, two kinds of muscle relaxants are described. First a nondepolarizing muscle relaxant and the second kind is the depolarizing muscle relaxant. These two kinds of muscle relaxants can be distinguished by rapidly stimulating the nerve 4 times over 2 seconds (Train of four or TOF). The nondepolarizing muscle relaxants produce fade ie successive muscle contractions are less forceful than the preceding ones. Whereas the depolarizing muscle relaxants are generally believed to produce four contractions of equal strength. However, there is some indication that this may not be entirely correct. There is evidence that depolarizing muscle relaxants also may produce fade. The investigators are conducting the following study to determine if indeed depolarizing muscle relaxants produce fade. The investigators would also like to characterize the fade ie differences during onset and offset of the block and the effect of the dose on the degree on the fade.

详细描述

Muscle relaxants are frequently employed during anesthesia. These medications may be employed to facilitate tracheal intubation, mechanical ventilation or to allow better surgical access. All muscle relaxants act at the neuromuscular junction. Based on the mechanism of action, two kinds of muscle relaxants have been defined1. Nondepolarizing muscle relaxants are competitive antagonists of the neurotransmitter acetylcholine (Ach) at the neuromuscular junction. The second kind of muscle relaxant is the depolarizing muscle relaxant and succinylcholine is the only muscle relaxant in this class that is clinically used. The mechanism of action of succinylcholine is less clear. Succinylcholine appears to mimic the actions of acetylcholine but results in a longer duration of depolarization of the post synaptic membrane1.

The degree of muscle relaxation produced by these muscle relaxants is measured by stimulating a motor nerve and measuring either the force of the muscle contraction produced or its compound muscle action potential (CMAP). As the muscle relaxation increases, the force of muscle contraction or the amplitude of the electromyogram (EMG) is correspondingly reduced.

On occasion, to measure the degree of muscle weakness or paralysis caused by a muscle relaxant, instead of a single stimulus, trains of stimuli are applied2. One method of repetitive stimulation is to apply four stimuli over a two second period. This method of nerve stimulation is called Train-of-Four (TOF). When this form nerve stimulation (TOF) is applied to patients who have been given nondepolarizing muscle relaxants -there is fade. Fade means that the force of successive muscle contractions is less than the preceding contraction3. The second contraction is less than the first, the third less than the second and so on. The degree of fade appears to have some reasonably well defined relationship to the degree of relaxation produced3.

The classic teaching in the anesthetic literature is that depolarizing muscle relaxants do not produce fade upon repetitive stimulation. It means that upon repetitive stimulation, the successive contractions are similar. This is one of the defining features of a depolarizing block and is called a Phase I block. The traditional teaching is that when a depolarizing muscle relaxant is administered in large or repetitive doses, a Phase II block develops. The phase II block has characteristics similar to those of a nondepolarizing muscle relaxant (ie fade on repetitive or TOF stimulation). De Jong and Freund first proposed that this differentiation between deplolarizing and nondepolarizing block based upon fade may not be as clear cut. These investigators demonstrated that succinylcholine caused fade upon repetitive stimulation right from the outset of the neuromuscular block. Other investigators have also demonstrated that succinylcholine causes fade from the initiation of the neuromuscular block. If it can be conclusively demonstrated that succinylcholine causes fade, then fade would be less useful in differentiating a depolarizing from a nondepolarizing block. We have previously investigated and defined the fade caused by nondepolarizing muscle relaxants. Using the experience we have gained in studying fade with nondepolarizing muscle relaxants, we would like to now define the characteristics of fade (if any) caused by succinylcholine.

Method: We intend to enroll fifty healthy adults, 18-60 years of age of either sex who are scheduled to undergo a surgical procedure under general anesthesia. Only subjects with a BMI <25 Kg/m2 will be enrolled. Only subjects free from any hepatic or renal disease will be included. We will exclude any subjects with known allergy to succinylcholine, family history of malignant hyperthermia or any history of skeletal myopathy. We will also exclude subjects that have recently sustained burns, or any illness resulting denervation injury (paraplegia or hemiplegia).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ASA PS I or II,
  • 18-60 years of age of either sex,
  • with a BMI<25Kg/m2

排除标准

  • presence of any disease involving the neuromuscular system.
  • Presence of any neurologic illness eg . Paraplegia or hemiplegia, spinal cord injuries, stroke, multiple sclerosis.
  • No liver or kidney disease.
  • Known allergy to succinylcholine.
  • Family history of malignant hyperthermia.
  • Known pseudocholinesterase deficiency.
  • Any skin burns within the last 1 year.
  • We would also exclude subjects with;
  • Central core disease,
  • duchenne or Becker muscular dystrophy,
  • osteogenesis imperfecta,
  • Noonan syndrome,
  • arthrogryposis multiplex,
  • congenital,
  • myotonia,
  • neuroleptic malignant syndrome,
  • multiminicore disease,
  • King Denborough syndrome,
  • Native American myopathy,
  • hypokalemic periodic paralysis or
  • a history of rhabdomyolysis.
  • We would also exclude any subject with a history of cardiac arrhythmias.

研究组 & 干预措施

0.25 mg/kg

Experimental

Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable

干预措施: Succinylcholine (Drug)

01 mg/kg

Experimental

Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable

干预措施: Succinylcholine (Drug)

0.15 mg/kg

Experimental

Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable

干预措施: Succinylcholine (Drug)

0.2 mg/kg

Experimental

Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable

干预措施: Succinylcholine (Drug)

0.3 mg/kg

Experimental

Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable

干预措施: Succinylcholine (Drug)

结局指标

主要结局

Fade on Train of Four Stimulation

时间窗: for the duration of the effect of succinylcholine generally expected to be 6-10 minutes

We stimulated the ulnar nerve at the wrist four times (over 1.5 seconds) every 20 seconds. We measured the ratio of the fourth contraction to the first contraction before and after the administration of succinylcholine. Before administering succinylcholine the ratio is normally one. After the administration of succinylcholine the first contraction diminishes, but the fourth contraction diminishes even more. This results in a ratio of T4 to T1 being less than one. The lowest ratio recorded after the administration after the administration of succinylcholine is reported as our outcome measure.

次要结局

未报告次要终点

研究者

发起方
University of Toledo Health Science Campus
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shashi Bhatt, MD

Associate Professor

University of Toledo Health Science Campus

研究点 (1)

Loading locations...

相似试验